Eli Lilly Stock Rallies 4.5% on Strong Foundayo Sleep Apnea Results

Eli Lilly and Company (LLY) experienced a significant boost on the stock market, with shares rising 4.5% to reach $1,414.93. This increase comes on the heels of positive Phase 3 clinical trial results for its obesity treatment drug, Foundayo, in relation to sleep apnea.

Positive Clinical Trial Findings

The results were part of the ATTAIN-OSA clinical program, which focused on adults experiencing moderate to severe obstructive sleep apnea in conjunction with obesity or being overweight. The data indicated that Foundayo notably alleviated the severity of sleep apnea symptoms, showcasing a reduction in breathing interruptions and notable weight loss among participants.

Impact of Foundayo on Sleep Apnea Symptoms

The trial results revealed that, after a 52-week period, patients not using positive airway pressure (PAP) therapy experienced a remarkable 43.8% reduction in sleep apnea events. Specifically, the treatment cut down the average number of apneas and hypopneas by 21.1 interruptions per hour from an initial average of 50.7.

• Nearly half (47.2%) of those not on PAP recorded a decrease of at least 50% in their apnea-hypopnea index.
• Among participants utilizing PAP therapy, a 27.5% reduction in sleep apnea events was also observed, with 33.7% achieving similar reductions.
• Remarkably, 19.6% reached remission or were classified as having a mild condition following treatment.

Moreover, Foundayo not only helped lower sleep apnea incidents but also contributed to weight loss. The average weight reduction was reported at 11.5% for those not on PAP therapy and 11.2% for participants who used it during the trial.

Future Regulatory Steps for Foundayo

Buoyed by the promising results, Eli Lilly has announced plans to submit Foundayo for FDA approval for its use in treating obstructive sleep apnea by the end of 2026. This step aims to broaden treatment options for adults dealing with both obesity and moderate to severe sleep apnea, though final approval is contingent on a thorough review by regulatory bodies.

Throughout the trial, the most frequently reported adverse effects included gastrointestinal issues such as nausea, diarrhea, and constipation. Among participants not using PAP therapy, 12.2% discontinued Foundayo due to these adverse events, contrasting with only 3.8% of the placebo group.

In contrast, among PAP users, 6.8% stopped taking Foundayo compared to just 0.6% in the placebo group. Despite these challenges, the overall findings add to Eli Lilly’s growing clinical insights into conditions tied to obesity.

Implications for the Cardiometabolic Portfolio

The encouraging trial results position Eli Lilly strongly within the cardiometabolic treatment field, further enhancing its portfolio designed to address obesity-related health issues. The anticipated FDA submission marks a critical future milestone for Foundayo's application in the treatment of sleep apnea.

As sleep apnea affects an estimated 936 million adults globally, and many remain undiagnosed, the potential for Foundayo to bridge treatment gaps is significant. Eli Lilly's commitment to expanding its therapeutic offerings exemplifies its focus on addressing complex health challenges.